| Literature DB >> 25856678 |
Mohamed Ali Abol Hassan1, Razina Rouf2, Evelin Tiralongo3, Tom W May4, Joe Tiralongo5.
Abstract
Lectins are non-immunoglobulin proteins that bind diverse sugar structures with a high degree of selectivity. Lectins play crucial role in various biological processes such as cellular signaling, scavenging of glycoproteins from the circulatory system, cell-cell interactions in the immune system, differentiation and protein targeting to cellular compartments, as well as in host defence mechanisms, inflammation, and cancer. Among all the sources of lectins, plants have been most extensively studied. However, more recently fungal lectins have attracted considerable attention due to their antitumor, antiproliferative and immunomodulatory activities. Given that only 10% of mushroom species are known and have been taxonomically classified, mushrooms represent an enormous unexplored source of potentially useful and novel lectins. In this review we provide an up-to-date summary on the biochemical, molecular and structural properties of mushroom lectins, as well as their versatile applications specifically focusing on mushroom lectin bioactivity.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25856678 PMCID: PMC4425051 DOI: 10.3390/ijms16047802
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Mushroom lectins and their specificity.
| Source of Lectin (Current Species Names Given in Parentheses) | Specificity of Sugars/Glycoproteins * | Ref. |
|---|---|---|
| Inulin | [ | |
| GalNAc, Galβ1,3GalNAc (T antigen), sialyl-Galβ (ABL) ‡ | [ | |
| Lac | [ | |
| Methyl | [ | |
| GalNAc, Gal, Suc | [ | |
| Lac, GlcNAc, Glc, Rham | [ | |
| Lac, BSM, Glycophorin A, k-Casein, β-galactosides, Gal (AAL galectin), terminal non-reducing GlcNAc (AAL2) | [ | |
| Trisaccharides containing Neu5Acα2,3Gal, Lac, sialic acid, inulin (ACG) | [ | |
| [ | ||
| [ | ||
| Gal, GalNAc, Rham | [ | |
| GIcNAcβ1, 4ManβpNP, Galβ1,4GlcNAcβ1,4GIcNAc, Galβ1,4GIcNAcβ1,4GlcNAc, BSM, asialo-BSM | [ | |
| Ovomucin, human glycophorin A (A. | [ | |
| Blood group specific substance B, A and H, bovine thyreoglobulin, ovomucoid, asialo-ovomucoid transferrin, Ovine submaxillary mucin, 4-nitrophenyl-α- | [ | |
| [ | ||
| Inulin (ALL) | [ | |
| Raf, Gal, ovomucoid and β-anomers of galactoside (Lac, | [ | |
| GlcNAcβ1,2Manα1,3(GlcNAcβ1,2Manα1,6)Manβ1,4GlcNAcβ1, 4GlcNAc, GlcNAc (BLL) | [ | |
| [ | ||
| [ | ||
| [ | ||
| Asialofetuin, Galβ1,4GlcNAcβ1,4Manβ1,4GlcNAcβ1,4GlcNAc residues in | [ | |
| Neu5Ac | [ | |
| Neu5Gc, GalNAc, asialo-BSM, PSM | [ | |
| GalNAc | [ | |
| Asialo-BSM, α-Gal, Galα1,3Gal, Raf | [ | |
| GalNAc, Lac, Glc | [ | |
| Asialo-fetuin, Lac, GalNAc, Gal, | [ | |
| [ | ||
| GlcNAc, Lac, Gal, Ara, Rib, Xyl | [ | |
| β-Gal (CCL2), GlcNAcβ1,4(Fucα1,3)GlcNAc (CGL2), GalNAcβ1,4GlcNAc (CGL3) | [ | |
| Lac, Gal, GalNAc | [ | |
| Sialoglycoprotein, Neu5Ac (CML) | [ | |
| Gal | [ | |
| β- | [ | |
| GalNAc, α- | [ | |
| [ | ||
| Asialo-triantennary | [ | |
| Terminal GalNAc residues, porcine stomach mucin, linear | [ | |
| Neu5Gc, Neu5Ac, inulin (HEA) | [ | |
| Lac, | [ | |
| α1,6-mannobiose, Isomaltose (Glcα1,6Glc), isomaltotriose, isomaltotetraose, isomaltopentaose, isomaltohexaose, methyl α-mannoside, α1,3-mannobiose, methyl β-mannoside, α1,2-mannobiose, α1,4-mannobiose, methyl α-glucoside, Man, lacturose (HRL) | [ | |
| GalNAc | [ | |
| Raf, | [ | |
| Methyl-β-galactoside, Fuc, | [ | |
| Asialo-PSM, asialofetuin, fetuin, α1-acid glycoprotein, Ovomucoid | [ | |
| [ | ||
| [ | ||
| Galβ1,3GalNAc | [ | |
| Galβ1,3GalNAc | [ | |
| [ | ||
| Asialofetuin, asialo-PSM and other desialylated glycoproteins | [ | |
| GalNAc, 4-nitrophenyl-β- | [ | |
| α-phenyl | [ | |
| Galβ1,3GalNAc | [ | |
| LacNAc, | [ | |
| GlcNAc, GalNAc, Man, | [ | |
| Raf, | [ | |
| Glc, GlcNAc, Man | [ | |
| Lac, Arab, MethGLc, GalNAc | [ | |
| Gal,Fuc, Suc, Arab | [ | |
| Galabiose-Galα1,4Gal, non-reducing α-Gal | [ | |
| Terminal | [ | |
| Galα1,3Galβ1,4GlcNAc, blood group Btrisaccharide (Galα1,3Gal2,1αFuc), Man, thyroglobulin, asialofetuin, complex type | [ | |
| Gal, Rham, Lac | [ | |
| [ | ||
| Asialo-BSM, BSM | [ | |
| Lac, Gal, Ara, Rib | [ | |
| β-GalNAc, terminal GlcNAc | [ | |
| [ | ||
| Asialo-PSM, asialofetuin, fetuin, α1-acid glycoprotein ( | [ | |
| Sialic acid and sialoglycoprotein (PJA) | [ | |
| [ | ||
| GalNAc (PAL1 and PAL2) | [ | |
| Fetuin | [ | |
| Lac, Gal | [ | |
| Inulin (PAL) | [ | |
| Asialofetuin | [ | |
| α1,6-fucosylated | [ | |
| GalNAc, asialo-BSM, | [ | |
| Mal, | [ | |
| Asialo-mucin | [ | |
| Methyl-α- | [ | |
| Me-α-GalNAc and 2'-fucosyllactose (Fucα1,2Galβ1,4Glc), | [ | |
| GalNAc | [ | |
| Lac | [ | |
| GlcNAc | [ | |
| [ | ||
| Neu5Acα2,6Galβ1,4Glc/GlcNAc (6'-sialylated type II chain) of | [ | |
| GlcNAc (PAL) | [ | |
| GlcNAc, Neu5Acα2,3Galβ1,4GlcNAc, Heparin and Pectin (PVL) | [ | |
| [ | ||
| Inulin, | [ | |
| Inulin, | [ | |
| Asialofetuin, asialo-PSM, fetuin, ovomucoid, α1-acid glycoprotein | [ | |
| GalNAc ( | [ | |
| [ | ||
| Gal | [ | |
| Lac, Gal, GalNAc | [ | |
| Lac (TML1), GalNAc and Gal (TML2) | [ | |
| Thyroglobulin (VVL) | [ | |
| Asialofetuin, asialo-PSM and other desialyzed glycoproteins Sychrova, GalNAc, Gal,TF antigen (XCL) | [ | |
| Inulin ( | [ | |
| Inulin, Xyl ( | [ |
* Ara, arabinose; BSM, Bovine submaxillary mucin; Fru, fructose; Gal, galactose; Glu, glucose; GalNAc, N-acetyl-d-galactosamine; GlcNAc, N-acetyl-d-glucosamine; Lac, lactose; Man, mannose; Mel, Melibiose; Neu5Gc, N-glycolyl-neuraminic acid; Neu5Ac, N-acetyl-neuraminic acid; PSM, Procine submaxillary mucin Raf, raffinose; Rham, rhamnose; Rib, ribose; Sor, sorbitol, Suc, sucrose; Xyl, xylose; The species name was incorrectly spelt in the original publication (in square brackets), the correctly spelt name has now been provided; ^ Names could not be matched to the global fungi name databases. “Clitocybe geophyla” as reported by Mikiashvili et al. (2006) [47] could be “Clitocybe geotropa” or “Inocybe geophylla”. “Paecilomyces japonica” as reported by Park et al. (2004) [127] could be Isaria japonica Yasuda, in which case the current name is Isaria tenuipes following Luangsa-ard et al. (2005) [163]; ‡ These abbreviated lectin names are provided for those mushroom species that are mentioned in Section 4 and Section 5 and also for mushroom species that have two or more lectins.
Common structural characteristics and strategies used to purify mushroom lectins for which crystal structure data exists.
| Lectin | Purification Strategy | Description of Lectin/Lectin Complex and Their PDB ID * | Resolution (Å) | Type of Fold #, PDB Structure and ID | Similarity to Other Structures and Their PDB ID | Ref. |
|---|---|---|---|---|---|---|
| Melibiose-sepharose | LDL (Ligand free)/4NDS | 1.00 | Two β-sheets linked by disulfide bridges: | Ginkbilobin-2/3A2E | [ | |
| LDL globotriose complex/4NDV | 1.00 | |||||
| LDL orthorhombic form/4NDT | 1.30 | |||||
| LDL α-methylgalactoside complex/4NDU | 1.03 | |||||
| (NH4)2SO4 precipitation, fucose-starch AC ^ | AAL (Ligand free)/1OFZ | 1.50 | Six-bladed β-propeller fold | [ | ||
| AAL complexed with Fuc/1IUC | 2.24 | |||||
| AAL (Hg-derivative from)/1IUB | 2.31 | |||||
| Chitin-sepharose AC, DEAE-cellulofine, CM-sepharose CL-6B | PVL (Ligand free)/2BWR | 1.50 | Integrin-like 7-blade β-propeller | [ | ||
| PVL GlcNAc complex/2C4D | 2.60 | |||||
| PVL Neu5Ac complex/2C25 | 1.80 | |||||
| PVL methyl 2-acetamido-1, 2-dideoxy-1-seleno-β- | 1.80 | |||||
| (NH4)2SO4 precipitation, DEAE-sepharose FF, Sephacryl S-200 HR, GF-250 HPLC | AAL-galectin (Ligand free)/2ZGK | 3.00 | ACG complexed with blood type A antigen tetraose/3WG3 | [ | ||
| Recombinant AAL-galectin (rAAL-galectin) (Ligand free)/2ZGL | 1.90 | |||||
| rAAL-galectin Lac complex/2ZGM | 1.90 | |||||
| rAAL-galectin Gal complex/2ZGN | 2.50 | |||||
| AAL-galectin mutant H59Q Lac complex/2ZGO | 2.00 | |||||
| AAL-galectin mutant I25G/2ZGP | 2.70 | |||||
| AAL-galectin mutant L33A/2ZGQ | 1.90 | |||||
| AAL-galectin mutant L33A/2ZGR | 1.90 | |||||
| AAL-galectin mutant L47A/2ZGS | 1.90 | |||||
| AAL-galectin mutant F93G/2ZGT | 2.80 | |||||
| AAL-galectin mutant I144G/2ZGU | 2.40 | |||||
| AAL-galectin TF antigen complex/3AFK | 1.95 | |||||
| AAL-galectin | 2.00 | |||||
| AAL-galectin mutant E66A | 2.10 | |||||
| AAL-galectin mutant R85A | 2.10 | |||||
| AAL-galectin ganglosides complex GM1 pentasaccharide/3M3Q | 2.10 | |||||
| (NH4)2SO4 precipitation, DEAE-cellulofine A-200, DEAE-Toyopearl 650M, and Toyopearl HW | ACG (Ligand free)/1WW7 | 1.90 | Recombinant (rAAL-galectin)/2ZGL | [ | ||
| ACG Lac complex/1WW6 | 2.20 | |||||
| ACG 3'-sulfonyl Lac complex/1WW5 | 2.20 | |||||
| ACG α2,3-sialyllactose complex/1WW4 | 2.30 | |||||
| ACG mutant (N46A) blood type A antigen tetraose complex/3WG4 | 1.60 | |||||
| ACG blood type A antigen tetraose complex/3WG3 | 1.35 | |||||
| Lactosyl-sepharose AC | CGL2 (Ligand free)/1UL9 | 2.22 | CGL3 chitotetraose complex/2R0H | [ | ||
| CGL2 Lac complex/1ULC | 2.60 | |||||
| CGL2 xeno linear trisaccharide complex/1ULE | 2.15 | |||||
| CGL2 blood group A tetrasaccharide complex/1ULF | 2.36 | |||||
| CGL2 TF antigen complex/1ULG | 2.20 | |||||
| CGL2 blood H Type II complex/1ULD | 2.20 | |||||
| CGL2 | 2.10 | |||||
| Lactosyl-sepharose AC | CGL3 (Ligand free)/2R0F | 2.00 | CGL2 | [ | ||
| CGL3 chitotetraose complex/2R0H | 1.90 | |||||
| DEAE cellulose, Superdex G75, MonoQ, Lipidex 1000 | BEL (Ligand free) form 1/4I4O | 1.12 | LSL | [ | ||
| BEL (Ligand free) form 2/4I4P | 1.28 | |||||
| BEL (Ligand free) form 3/4I4Q | 1.51 | |||||
| BEL (Ligand free) form 4/4I4R | 1.77 | |||||
| BEL lactose complex/4I4S | 1.40 | |||||
| BEL galactose complex/4I4U | 1.57 | |||||
| BEL | 1.50 | |||||
| BEL T-Antigen disaccharide complex/4I4X | 1.72 | |||||
| BEL T-Antigen complex/4I4Y | 1.90 | |||||
| Lactosyl and glucosyl-sepharose AC, Chromsep HPLC | CNL Lac complex at pH 4.4/3NBC | 1.01 | Three Foil/3PG0 | [ | ||
| CNL Lac complex at pH 7.1/3NBD | 1.15 | |||||
| CNL | 1.86 | |||||
| Horseradish Peroxidase AC | CCL2 (Ligand free)/2LIE | NA | Mosquitocidal toxin/2VSE | [ | ||
| CCL2 nematode glycan complex/2LIQ | ||||||
| Lactose-sepharose AC | LSL (Ligand free)/1W3A | 2.65 | [ | |||
| LSL | 2.68 | |||||
| LSL | 2.58 | |||||
| LSL (recombinant)/2Y9F | 1.47 | |||||
| LSL (recombinant) Lac complex/2Y9G | 1.67 | |||||
| (NH4)2SO4 precipitation, melibiose-sepharose, Synsorb-type B trisaccharide, and Synsorb-type A trisaccharide AC | MOA Galβ1,3Galβ1,4-GlcNAc complex/2IHO | 2.41 | Three Foil/3PG0 | [ | ||
| MOA Galα1,3(Fucα1,2)Gal and calcium complex/3EF2 | 1.80 | |||||
| Lactosyl-Sepharose AC | MPL (ligand free)/4ION | 1.60 | [ | |||
| MPL Gal complex/4IYB | 1.59 | |||||
| MPL Lac complex/4IZX | 1.1 | |||||
| MPL | 1.4 | |||||
| (NH4)2SO4 precipitation, β- | PSL bound to human-type influenza-binding epitope Neu5Ac α2-6Galβ1-4GlcNAc/3PHZ | 1.70 | ThreeFoil/3PG0 | [ | ||
| Human erythrocytic stroma polyacrylamide gel AC, preparative isoelectric focusing to separate the 5 ABL isoforms | ABL (Ligand free)/1Y2T | 1.50 | [ | |||
| ABL Lacto- | 1.85 | |||||
| ABL T-antigen complex/1Y2V | 1.90 | |||||
| Orthorhombic form of ABL T-antigen and GlcNAc complex/1Y2W | 1.74 | |||||
| Tetragonal form of ABL T-antigen and GlcNAc complex/1Y2X | 2.36 | |||||
| Chitin-sepharose AC, Superdex G-200 HR, Lipidex 1000; Human erythrocytic stroma polyacryl-amide gel AC, Superdex G-200 HR, Lipidex 1000 resin, MiniQ PE | BEL (Ligand free)/3QDS | 1.15 | [ | |||
| BEL T-antigen complex/3QDT | 1.30 | |||||
| BEL | 2.00 | |||||
| Orthorhombic form of BEL GlcNAc and GalNAc complex/3QDV | 1.30 | |||||
| Hexagonal form of BEL GlcNAc and GalNAc complex/3QDW | 1.90 | |||||
| Orthorhombic form of BEL T-antigen disaccharide and | 1.70 | |||||
| Hexagonal form of BEL T-antigen disaccharide and | 2.00 | |||||
| Fetuin-sepharose | Wild-type XCL (ligand free)/1XI0 | 2.00 | [ | |||
| XCL mutated at Q46M, V54M, L58M/1X99 | 1.40 | |||||
* For further lectin-related tools and databases please see the Lectin 3D structure database (http://glyco3d.cermav.cnrs.fr) or the CAZy database (http://cazy.org); ^ AC, Affinity Chromatography; # Only symmetrical, ligand free structures are shown; NA, Not Available.
Antiproliferative/antitumor and mitogenic activity of mushroom lectins.
| Antiproliferative/Antitumor Activity | |||
|---|---|---|---|
| Source of Lectin | IC50 | Cell Type/Target | Ref. |
| 50 µg/mL * | HT-29 | [ | |
| NA | S-180, Hela, SW480,SGC 7901, MGC80-3, BGC-823, HL-60 | [ | |
| 1.7 µg/mL * | L1210 | [ | |
| 2.5 μM | MBL2 | [ | |
| 15 µg/mL | U937 | [ | |
| NA | Mo-T, Jurkat | [ | |
| 0.5–0.6 mg/mL * | HepG2 | [ | |
| 13 μM | L1210 | [ | |
| 8 μM | L1210 | [ | |
| 25 μg/mL * | HeLa | [ | |
| 56.1 μM | HepG2 | [ | |
| 3.5 μM | HepG2 | [ | |
| 7.4 μM | MCF7 | ||
| 8.90 μM | HepG2 | [ | |
| NA | SNU-1, AsPc-1, MDAMB-231 | [ | |
| NA | A-549, HCT-8 | [ | |
| 2.1 μM | HepG2 | [ | |
| 5 mg/kg of body weight/day ¥ | S-180 in ICR mice | [ | |
| 2 μg/mL | MCF-7, K562, HEP-2 | [ | |
| 1.5 mg/kg bodyweight/day ¥ | S-180, H-22 | [ | |
| NA | M1, Herto, S180 | [ | |
| 0.48 μM | HT29 | [ | |
|
| 0.88 μM | HepG2 | [ |
| 30 μg/mL | KB | [ | |
| NA | P815, PU5-1.8 | [ | |
| 17.5 mg/kg body weight ¥ | S-180 | [ | |
| NA | Hela, NIH-3T3 | [ | |
| 1.24 μM | M1 | [ | |
| 2 µM | Mouse splenocytes | [ | |
| 1 µM | Mouse splenocytes | [ | |
| 1 µM | Mouse splenocytes | [ | |
| 26 µM | Mouse splenocytes | [ | |
| 100 µM | Mouse spleen lymphocytes | [ | |
| 20 µM | Mouse splenocytes | [ | |
| 1.5 µM | Mouse splenocytes | [ | |
| 0.15 µM | Mouse splenocytes | [ | |
| 8 µM | Mouse splenocytes | [ | |
| 2 µM | Mouse splenocytes | [ | |
| 62.5 µM | Mouse splenocytes | [ | |
| 4 µM | Mouse splenocytes | [ | |
| 31.25 µM | Mouse splenocytes | [ | |
NA: Not Available; * The concentration or range of titer found effective for antiproliferative/antitumor activities; ¥ The dosage found effective for in vivo antiproliferative/antitumor activities; £ This is the minimum lectin concentration for mitogenic activity.
Anti-HIV-1 reverse transcriptase activity of mushroom lectins.
| Source of Lectin | IC50 | Ref. |
|---|---|---|
| 8.0 µM | [ | |
| 14.3 µM | [ | |
| 10.0 µM | [ | |
| 31.7 µM | [ | |
| 4.7 µM | [ | |
| 0.93 µM | [ | |
| 1.2 µM | [ |